Market Overview

Global Antimicrobial Resistance Diagnostics Market 2018-2023: Strategies & Trends By Pathogen And Technology - 6 Key Large Pathogen Opportunities


Dublin, July 30, 2018 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostics Market, Strategies & Trends By Pathogen And Technology With Executive Guides And Customization 2018 To 2023" report has been added to's offering.

Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed.

We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.

Key Topics Covered:

1. Introduction and Market Definition
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size
1.3 Methods and Sources

1.4 U.S. Antibiotic Markets - Perspective
1.4.1 U.S. Outpatient Use of Antibiotics
1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market
2.1 Market Players - Roles & Impacts
2.1.1 Drug manufacturers - Larger/pharmaceutical
2.1.2 Drug manufacturers - Generic
2.1.3 Contract Research and Manufacturing
2.1.4 In Vitro Diagnostics Industry
2.1.5 Drug Marketing Companies
2.1.6 Biotechnology Companies
2.1.7 Regulatory Bodies
2.2 Understanding Antimicrobial Resistance
2.2.1 What is Antimicrobial Resistance (AMR)
2.2.2 Bacteria and Other Microbes 2.2.3 The History of Antibiotics
2.2.4 The Role of Animal Husbandry
2.2.5 The Implications of Horizontal Transfer
2.2.6 The Threat of AMR
2.3 The Changing Road to New Antibiotics & Technologies
2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP)
3.1.2 Campylobacter (DRC)
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Diagnostic Technology Development Opportunities
3.2.1 What's Wrong with Microbiology
3.2.2 The Features Battleground of Infectious Disease Diagnostics
3.2.3 Multiplex vs. POC/Rapid
3.2.4 The Miracle of Genetics
3.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing
3.2.7 Markers of Resistance
3.2.8 What Happens to the Microbiology Lab?
3.4. Antibiotic Resistance Recent Developments
3.4.1 Recent Developments - Importance and How to Use This Section
3.4.2 Importance of These Developments
3.4.3 How to Use This Section
3.4.4 Quick identification of multidrug-resistant pathogens 3.4.5 Metagenomics Enables Researchers to Uncover Drug Resistance Genes
3.4.6 Rapid detection of multi-drug-resistant bacteria
3.4.7 Improved Diagnostics Fail to Halt the Rise of Tuberculosis
3.4.8 High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
3.4.9 New solution for diagnosing antibiotic-resistant bacteria
3.4.10 MALDI-TOF - Results in Minutes not Days
3.4.11 CRISPR Tool Used to Uncover Infections
3.4.12 Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
3.4.13 BD, Check-Points Receive CE Mark for Resistant Organism Screening Test 3.4.14 LiDia BSI Detects Pathogens and Antimicrobial Resistance
3.4.15 New tool can Track Resistant Malaria
3.4.16 Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
3.4.17 Longitude Funds for POC Tests
3.4.18 New test can identify dangerous bacteria with resistance to last-resort antibiotic
3.4.19 bioMrieux receives FDA clearance for expanded pathogen identification capability
3.4.20 OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
3.4.21 Hospital Plumbing Harbors Antibiotic Resistant Bacteria
3.4.22 Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
3.4.23 Curetis Gets Singapore Approval for Pneumonia Test
3.4.24 PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
3.4.25 Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies
3.4.26 Fusion Genomics Developing All Pathogens Diagnostic

4. Key Biotechnology Companies and Their Technology
4.1 Diagnostics
4.1.1 1928 Diagnostics
4.1.2 Sense Biodetection
4.1.3 Fusion Genomics
4.1.4 Day Zero Diagnostics
4.1.5 Inflammatix
4.1.6 Hutman Diagnostics
4.1.8 bioMrieux Diagnostics
4.1.9 Curetis N.V. / Curetis GmbH
4.1.10 Great Basin Corporation
4.1.11 Becton, Dickinson and Company
4.1.12 Roche Diagnostics
4.1.13 Cepheid (now Danaher)
4.1.14 Atlas Genetics
4.1.14 Accelerate Diagnostics
4.1.15 Seimens
4.1.16 Abbott Diagnostics
4.1.17 Thermo Fisher
4.1.18 Bio - Rad
4.1.19 Sysmex
4.1.20 Ortho Clinical

5. The Global Market
5.1 Global Market by Country

6. Global Market by Pathogens
6.1 Global Market by Pathogens
6.2 DRSP
6.3 DRC
6.4 CD
6.5 MRSA
6.5 DRNG

7. AMR Diagnostics by Technology
7.1 Global Market by Technology
7.2 Bacterial Culture
7.3 Immunoassay
7.4 Polymerase Chain Reaction
7.5 Genetic Sequencing
7.6 Mass Spectrometer
7.7 Rapid, POC and Other

8. Vision of the Future of AMR Diagnostics

For more information about this report visit

         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Diagnostics

Primary Logo

View Comments and Join the Discussion!
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.